CHAD Therapeutics Inc. received the Frost & Sullivan Product Line Strategy Leadership Award for oxygen therapy at the Medtrade Spring Exposition and Conference in Las Vegas.
The Frost & Sullivan Award for Oxygen Therapy Product Line Strategy Leadership is presented each year to the company that has demonstrated the most insight into customer needs and product demands. The recipient company has optimized its product line by leveraging products with the various price, performance and feature points required by the market. To select the award recipient, the analyst team tracks all end-user requirements and market dynamics with the industry. This process includes interviews with suppliers, end-users and industry experts. The product lines are compared with customer base demands, and the top-ranking supplier is then presented the Award.
Greg Caressi, vice president of Healthcare and Life Sciences for Frost & Sullivan, presented the award. On hand to receive the award were CHAD’s president and chief executive officer, Earl Yager; chairman of the board, Tom Jones; and vice president of sales and marketing, Erika Laskey.
Visit www.chadtherapeutics.com.